
Therapy Acceleration Program[®] (TAP): filling a "gap" in our research programs



Therapy Acceleration Program® (TAP)

More Therapies to More Patients, Faster

Biotechnology Accelerator

Funding is project specific, tranched, current high \$12.5M

Academic Concierge

Funding is project specific, tranched, current high \$6M

Clinical Trials Program

Funding is project specific, tranched, current high \$>1M

Special Initiatives

Funding is project specific, tranched, current high \$ >8M

47 collaborations and supported projects; ~ \$78 million invested



Blood Cancer Research Partnership (BCRP)



DANA-FARBER
CANCER INSTITUTE

- Goal: Establish a network to accelerate the development of and expand access to well-designed and innovative clinical trials for blood cancer patients being treated at community sites
- Why did we establish BCRP:
 - Over 80% of patients with cancer in the United States are being treated in the community
 - Only 5% of patients with hematological malignancies participate in clinical trials

Partners:

- A leading academic cancer institute (Dana-Farber Cancer Institute, DFCI)
- A premier foundation (The Leukemia and Lymphoma Society)
- A select group of community oncologists -11 sites across the continental US

BCRP Operation and Outcome

- LLS provides infrastructure support to DFCI, no funding for the trials
- Mutually agreed Milestones and Deliverables

Trial	Enrollment Rate Increase	Enrollment Time Decrease (est.)
BCRP-001	235% in Part B	1 year for Part B
BCRP-002	54%	3 months
BCRP-003	115%	6 months

- Trials need the approval of all partners
- Biweekly enrollment update; monthly meeting; quarterly formal progress review; annual BCRP investigator summit
- 18-month Outcome:
 - Three trials open at BCRP sites
 - Four trials open soon
 - Four trials in development
 - Presentation at scientific conferences
 - Addition of BCRP sites has increased screening and enrollment when compared to DFCI alone thus shortened the trials



